<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Nafcillin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00607</strong>&#160; (APRD01130, DB08269)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>A semi-synthetic antibiotic related to penicillin. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00607/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00607/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00607.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00607.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00607.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00607.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00607.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00607">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Nafcilina</td><td>Spanish</td><td>INN</td></tr><tr><td>Nafcilline</td><td>French</td><td>INN</td></tr><tr><td>Nafcillinum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Nafcillin Sodium</strong>
          <div class="cas">985-16-0</div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000497/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000497/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: AYAPZOUDXCDGIF-FRFVDRIFSA-M</li>
              <li>Monoisotopic Mass: 436.106887157</li>
              <li>Average Mass: 436.457</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000497">DBSALT000497</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Nallpen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Unipen</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-bacterial-agents">Anti-Bacterial Agents</a></li>
<li><a href="/mesh/penicillins">Penicillins</a></li></ul></td></tr><tr><th>CAS number</th><td>147-52-4</td></tr><tr><th>Weight</th><td>Average: 414.475<br>Monoisotopic: 414.124942514</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>22</sub>N<sub>2</sub>O<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>GPXLMGHLHQJAGZ-JTDSTZFVSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(2S,5R,6R)-6-(2-ethoxynaphthalene-1-amido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)C1=C(OCC)C=CC2=CC=CC=C12)C(O)=O</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactams</td></tr><tr><th>Subclass</th><td>Beta Lactams</td></tr><tr><th>Direct parent</th><td>Penicillins</td></tr><tr><th>Alternative parents</th><td>Naphthalenecarboxamides; N-acyl-alpha Amino Acids and Derivatives; Salicylic Acid and Derivatives; Benzamides; Phenol Ethers; Benzoyl Derivatives; Alkyl Aryl Ethers; Tertiary Carboxylic Acid Amides; Thiazolidines; Tertiary Amines; Hemiaminals; Azetidines; Secondary Carboxylic Acid Amides; Carboxylic Acids; Enolates; Polyamines; Aminals; Thioethers</td></tr><tr><th>Substituents</th><td>1-naphthalenecarboxylic acid or derivative; n-acyl-alpha amino acid or derivative; 1-naphthalenecarboxamide; acene; naphthalene; salicylic acid or derivative; benzamide; phenol ether; benzoyl; alkyl aryl ether; benzene; tertiary carboxylic acid amide; thiazolidine; carboxamide group; azetidine; tertiary amine; secondary carboxylic acid amide; hemiaminal; polyamine; carboxylic acid; carboxylic acid derivative; ether; aminal; enolate; thioether; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the penicillins. These are organic compounds containing the penicillin core structure, which is structurally characterized by a penam ring bearing two methyl groups at position 2, and an amide group at position 6 [starting from the sulfur atom at position 1].</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs.</td></tr><tr><th>Pharmacodynamics</th><td>Nafcillin is a semisynthetic antibiotic substance derived from 6-amino-penicillanic acid. The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase-producing and non penicillinase-producing strains of Staphylococcus aureus. The penicillinase- resistant penicillins are active in vitro against a variety of other bacteria.</td></tr><tr><th>Mechanism of action</th><td>Penicillinase-resistant penicillins exert a bactericidal action against penicillin-susceptible microorganisms during the state of active multiplication. All penicillins inhibit the biosynthesis of the bacterial cell wall.</td></tr><tr><th>Absorption</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>89.9 &#177;1.5%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic metabolism accounts for less than 30% of the biotransformation of most penicillins.</p></td></tr><tr><th>Route of elimination</th><td>Nafcillin is primarily eliminated by nonrenal routes, namely hepatic inactivation and excretion in the bile.</td></tr><tr><th>Half life</th><td>The serum half-life of nafcillin administered by the intravenous route ranged from 33 to 61 minutes as measured in three separate studies.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Serious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.</td></tr><tr><th>Affected organisms</th><td><ul><li>Enteric bacteria and other eubacteria</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              -
        </td>
        <td>0.5328</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9938</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6248</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.708</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8782</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8807</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7898</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8164</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7263</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8869</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8082</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.5653</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7437</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.796
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6679
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9972
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1208 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9994
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6449
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Wyeth ayerst laboratories</li>
<li>Apothecon inc div bristol myers squibb</li>
<li>Marsam pharmaceuticals llc</li>
<li>Sandoz inc</li>
<li>Glaxosmithkline</li>
<li>Baxter healthcare corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.meadjohnson.com">Mead Johnson and Co.</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Solution</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Nafcillin alters serum levels of cyclosporine</td></tr><tr><td><a href="/drugs/DB00618">Demeclocycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00254">Doxycycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>This anti-infectious agent could decrease the effect of the oral contraceptive</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy will decrease levels of lurasidone via effects on CYP 3A4. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00563">Methotrexate</a></td><td>The penicillin increases the effect and toxicity of methotrexate</td></tr><tr><td><a href="/drugs/DB01017">Minocycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Nafcillin may decrease the plasma concentration of Telithromycin. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Nafcillin may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB00759">Tetracycline</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Nafcillin may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Nafcillin, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Nafcillin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated.  </td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Nafcillin may decrease the serum concentration of Verapamil by increasing its metabolism via CYP3A4. Monitor for changes in the therapeutic/adverse effects of Verapamil if Nafcillin is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Nafcillin may increase the anticoagulant effect of warfarin increasing the risk of bleeding. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of warfarin if nafcillin is initiated, discontinued or dose changed. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>